HIM
SGNT

Hillsdale Investment Management’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Hillsdale Investment Management’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,600
Closed -$40K – 605
2014
Q4 		$40K Buy
+1,600
New +$46.9K 0.01% 454

Other funds holding SGNT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hillsdale Investment Management's SGNT Position: Q1 2015 in Review

Hillsdale Investment Management sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q1 2015, closing a stake of 1,600 shares — an estimated $40K sold.

Hillsdale Investment Management first reported a position in SGNT in Q4 2014 and held it in 1 quarter. The position peaked at $40K in Q4 2014. 127 funds tracked by Wall St. Rank hold SGNT as of Q1 2015.

  • Hillsdale Investment Management reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q1 2015 after selling out during the quarter.
  • Hillsdale Investment Management sold 1,600 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q1 2015, an estimated $40K.
  • Hillsdale Investment Management first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q4 2014 and held it in 1 quarter.
  • Hillsdale Investment Management's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $40K in Q4 2014.
  • 127 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q1 2015.

Based on Hillsdale Investment Management's 13F filing for Q1 2015, filed 12 May 2015.